ArticleNature medicine2022
Author Correction: Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy.
Abstract readPublished Erratum
In one paragraph
Article in Nature medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Review
- Progressive disruption of hematopoietic architecture from clonal hematopoiesis to MDS.iScience · 2023Article
Corrections and comments
- Erratum for
Authors and funding
38 authors.
Irene Ganan-GomezDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0001-8354-3139
Hui YangDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Feiyang MaMolecular Biology Institute, University of California, Los Angeles, Los Angeles, CA, USA.ORCID http://orcid.org/0000-0002-6260-0787
Guillermo Montalban-BravoDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Natthakan ThongonDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Valentina MarchicaDepartment of Medicine and Surgery, University of Parma, Parma, Italy.
Guillaume Richard-CarpentierDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Kelly ChienDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0001-6024-1613
Ganiraju ManyamDepartment of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0001-6006-8961
Feng WangDepartment of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ana AlfonsoDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Shuaitong ChenDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Caleb ClassDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0003-3130-3613
Rashmi Kanagal-ShamannaDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0001-7829-5249
Justin P IngramAbbVie Oncology Discovery, Chicago, IL, USA.
Yamini OgotiDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ashley RoseDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Sanam LoghaviDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0001-8980-3202
Pamela LockyerDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Benedetta CamboDepartment of Medicine and Surgery, University of Parma, Parma, Italy.
Muharrem MuftuogluDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0001-8100-8554
Sarah SchneiderDepartment of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0001-7027-7978
Vera AdemaDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0001-6051-4378
Michael McLellanMcDonnell Genome Institute, Washington University in St. Louis, St. Louis, MO, USA.ORCID http://orcid.org/0000-0002-2703-8784
John GarzaMcDonnell Genome Institute, Washington University in St. Louis, St. Louis, MO, USA.
Matteo MarchesiniDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Nicola GiulianiDepartment of Medicine and Surgery, University of Parma, Parma, Italy.ORCID http://orcid.org/0000-0003-3457-3774
Matteo PellegriniMolecular Biology Institute, University of California, Los Angeles, Los Angeles, CA, USA.ORCID http://orcid.org/0000-0001-9355-9564
Jing WangDepartment of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0002-5398-0802
Jason WalkerMcDonnell Genome Institute, Washington University in St. Louis, St. Louis, MO, USA.ORCID http://orcid.org/0000-0001-7547-5789
Ziyi LiDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0001-8359-0533
Koichi TakahashiDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0002-8027-9659
Joel D LeversonAbbVie Oncology Discovery, Chicago, IL, USA.
Carlos Bueso-RamosDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Michael AndreeffDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0002-1144-1958
Karen Clise-DwyerDepartment of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Guillermo Garcia-ManeroDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0002-3631-2482
Simona CollaDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. scolla@mdanderson.org.ORCID http://orcid.org/0000-0001-6583-8910
Funding
Statistical models for intratumor heterogeneity of tumor-infiltrated leukocytes in lung cancerR03CA270725 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI LI, ZIYI · 2022 to 2023
$162kNCI NIH HHS R03 CA270725
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.